Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy

Last updated: September 24, 2024
Sponsor: Mayo Clinic
Overall Status: Completed

Phase

3

Condition

Obesity

Diabetes Prevention

Treatment

RYGB

Saxenda

Placebos

Clinical Study ID

NCT03115424
16-004253
  • Ages 20-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Observational studies suggest that bariatric surgery is the most effective intervention for weight loss. Comparative effectiveness of Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (SG) demonstrate that RYGB is significantly superior to SG in terms of weight loss and glycemic control. Both RYGB and SG increase GLP-1 concentrations which directly affect B-cell function. Data has shown that the postprandial rise in GLP-1 might affect feeding behavior after RYGB and to a lesser extent SG, where the increase in GLP-1 is less marked. In this study the investigators propose to randomize subjects undergoing SG to receive either placebo or Liraglutide, a GLP-1 receptor agonist, to compare weight loss and CV risk factors.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age 20-65 years of age

  2. Seen at Mayo Clinic Nutrition Clinic and have received authorization for bariatricsurgery.

  3. No active physical illness which will interfere with mobility or weight loss afterbariatric surgery.

  4. Females who are sexually active and able to become pregnant must agree to use birthcontrol for duration of study if randomized to Saxenda/Placebo.

Exclusion

Exclusion Criteria:

  1. Prior use of glucose lowering medication in the 3 months prior to screening.

  2. A fasting glucose ≥ 126mg/dl or an HbA1c ≥ 6.5% will be taken as evidence of type 2diabetes and therefore patients will be deemed ineligible for participation.

  3. Prior abdominal surgery other than cholecystectomy, appendectomy or hysterectomy.

  4. Pregnancy or active consideration of pregnancy during the period of study. Subjectswill be discontinued if they become pregnant during the study.

  5. Hypersensitivity to liraglutide or any product components.

  6. Personal or family history of medullary thyroid carcinoma or Multiple EndocrineNeoplasia type 2.

  7. Prior history of pancreatitis, cholelithiasis or cholecystitis.

  8. Concurrent use of insulin or any other GLP-1 receptor agonist.

  9. Active, severe psychiatric disease

Study Design

Total Participants: 46
Treatment Group(s): 3
Primary Treatment: RYGB
Phase: 3
Study Start date:
June 22, 2017
Estimated Completion Date:
May 30, 2024

Study Description

A total of 75, non diabetic adults, scheduled for bariatric surgery at Mayo Clinic Rochester, will be enrolled. Of these, 25 will be scheduled for Roux-en-Y Gastric Bypass surgery (RYGB), while the remainder (50) will be scheduled for Sleeve Gastrectomy (SG). The study team will play no role in assignment of the surgical procedure. Following surgery, at month 3, subjects undergoing SG will be randomized to either Saxenda or placebo, subcutaneously once daily. Subjects randomized to Saxenda or placebo will take for the duration of the study (33 months). Follow up study visits for all subjects will be timed to coincide with the standard clinical follow up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.

Connect with a study center

  • Mayo Clinic in Rochester

    Rochester, Minnesota 55905
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.